Indaptus Therapeutics, Inc. reported on December 22, 2025, that it entered into a Securities Purchase Agreement to sell 1,000,000 shares of convertible preferred stock at $6.00 each, raising $6.0 million with the proceeds intended for operations and other corporate needs. The offering closed on December 23, 2025.